Professional Overview

Sabah Oney is a seasoned executive currently serving as CEO at stealth biotech, Co-Founder, Interim CEO, and Member of the Board of Directors at Vilya, and CEO at ARCH Venture Partners. Her key expertise areas include business development, operations, and sales, with a strong industry focus on biotechnology and healthcare.

Experience Summary

Current Role

Sabah Oney currently holds multiple leadership positions, driving business growth and strategic development. As CEO at stealth biotech, she oversees overall strategy and direction. At Vilya, she co-founded the company and serves as Interim CEO and Board Member, guiding its development. Additionally, she is CEO at ARCH Venture Partners, leading investment and partnership initiatives.

Career Progression

Sabah Oney's career trajectory showcases progressive growth and significant contributions. Notable previous roles include Chief Business Officer at Full-time, Vice President of Business Development and Operations at Alector, and Head of Global Sales and Business Development at Ariosa Diagnostics. Her career is marked by increasing responsibility and achievement in the biotech and healthcare sectors.

Areas of Expertise

Sabah Oney's expertise encompasses industry-specific skills in biotechnology, technical competencies in business development and operations, and strong leadership and management capabilities. Her ability to drive growth, foster partnerships, and navigate complex business environments is noteworthy.

Professional Impact

While specific projects and initiatives are not detailed, Sabah Oney's current and past roles indicate significant contributions to the biotech and healthcare industries. Her leadership positions and career growth suggest a high level of professional impact and influence.

Conclusion

Sabah Oney's professional trajectory is marked by steady ascent and expanding responsibilities. Currently, her focus is on driving growth and strategy at stealth biotech, Vilya, and ARCH Venture Partners. Her value proposition lies in her unique blend of industry expertise, business acumen, and leadership capabilities, positioning her as a pivotal figure in the biotechnology sector.